17 results about "Phosphate binding agents" patented technology

The invention discloses a phosphate binder and a preparation method thereof, the phosphate binder is sucrose iron oxyhydroxide containing iron oxyhydroxide (III), sucrose and a mixture of one or more starches, the particle size range D50 of the sucrose iron oxyhydroxide is controlled to be 30.5-39.5 [mu] m or D90 is less than 200 [mu] m, so that tailing loss and material wall sticking in a spray drying process can be effectively reduced; the high yield of about 90% is obtained, and the iron release amount and the drying weight loss ratio are both superior to those of a small-particle-size group (D50lt; 30.5 [mu] m) and a large particle size group (D50gt; 39.5 [mu] m) or D90 is greater than 200 [mu] m, so that the stability of the pharmaceutical composition is improved; according to the preparation method disclosed by the invention, the D50 particle size distribution of the sucrose iron oxyhydroxide is controlled within a range of 30.5-39.5 microns or D90 less than 200 microns by regulating and controlling the solid content of the aqueous suspension of the iron oxyhydroxide (III), the sucrose and the starch, so that the product is high in yield and good in quality, and the economic value of industrial production of the product is greatly improved.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The invention belongs to the field of phosphate binders, and relates to a straight-chain saturated aliphatic dicarboxylic acid-iron (III) compound, a preparation method and application thereof, in particular to application of the straight-chain saturated aliphatic dicarboxylic acid-iron (III) compound in preparation of drugs for treating or preventing hyperphosphatemia. The molar ratio of iron element to dicarboxylic acid in the dicarboxylic acid-iron (III) compound is 1: (0.8-1.2), the dicarboxylic acid is straight-chain saturated aliphatic dicarboxylic acid, and the compound is prepared by reacting ferric salt and dicarboxylate in a solvent. An in-vitro phosphorus binding experiment proves that the dicarboxylic acid-iron (III) compound disclosed by the invention is high in phosphorus binding amount of iron per unit mass in a pH range of 3-7, can also keep very high phosphorus binding capacity of iron per unit mass in an animal body, and is obviously superior to commercially available sucrose iron oxyhydroxide chewable tablets. As an oral phosphorus binding agent, the compound disclosed by the invention is stronger in phosphorus binding capacity of unit mass of iron in vivo, high in iron utilization rate, small in total dosage of iron element and lower in adverse reaction.

To provide a refractory material for patching, which exhibits superior adhesion, anti-cracking effect, ease of trowel release, and storage stability, even with no use or significantly reduced use of a phosphate binder.SOLUTION: A refractory material for patching comprises a refractory aggregate, a refractory clay, and cellulose fibers having an average fiber length of 150 to 2000 μm. The content of the cellulose fibers is 0.3 to 40 wt.% externally calculated, with the sum of the refractory aggregate and the refractory clay being 100 wt.% (where the upper limit is 20 wt.% when the average fiber length of the cellulose fibers is more than 800 μm and 1400 μm or less, and the upper limit is 8 wt.% when the average fiber length of the cellulose fibers is more than 1400 μm and 2000 μm or less).SELECTED DRAWING: Figure 4(a)

The invention provides a baking-free prefabricated part for a rotary kiln and a preparation method of the baking-free prefabricated part. The baking-free prefabricated part for the rotary kiln is prepared from the following raw materials in parts by mass: 35-50 parts of fused magnesite, 20-40 parts of magnesium aluminate spinel, 0.5-5 parts of silica powder, 0.5-5 parts of silicon nitride fine powder, 1-6 parts of zirconium titanate, 1-6 parts of aluminum oxide hollow spheres, 1-8 parts of a phosphate binding agent and 1-6 parts of a water reducing agent. The baking-free prefabricated part for the rotary kiln has good strength performance, lower heat conductivity and better cement clinker corrosion resistance.

The invention relates to a fire-resistant and wear-resistant coating for a circulating fluidized bed boiler and a preparation method of the fire-resistant and wear-resistant coating. Comprising 40-50 parts by weight of white corundum, 5-15 parts by weight of modified fused mullite, 1-3 parts by weight of stainless steel short fibers, 1-3 parts by weight of a self-lubricating material, 3-5 parts by weight of silica powder, 3-5 parts by weight of a phosphate binder solution, 0.1-0.5 part by weight of a dispersant aqueous solution, 5-10 parts by weight of a plasticizer and 5-8 parts by weight of water. And cracking and falling are not prone to occurring.

The invention provides refractory mortar for a sliding nozzle and a preparation method of the refractory mortar, and belongs to the technical field of refractory materials, and the preparation method comprises the following steps: uniformly mixing aluminum hydroxide, water and phosphoric acid, heating for reaction, heating, adding boric acid, malic acid, tartaric acid and triethanolamine for continuous reaction, cooling to room temperature, and filtering to obtain a modified phosphate binder; the preparation method comprises the following steps: uniformly mixing zirconium powder and crystalline flake graphite, adding potassium chloride and sodium chloride, mixing and stirring, heating and reacting in inert gas, cooling, washing and drying to obtain a nanocrystalline ZrC coating graphite material; and ball-milling and mixing fused magnesite, silicon powder and Al-Si alloy powder, adding the modified magnesium aggregate, the nanocrystalline ZrC coating graphite material and the modified phosphate binder, uniformly mixing, discharging and packaging to obtain the refractory mortar for the sliding nozzle. The thermal shock resistance and slag corrosion resistance of the refractory mortar for the sliding nozzle can be improved.

The present application discloses compositions and principles for the prophylactic treatment of hypocalcemia in ruminants (e.g., cattle) prior to childbirth, i.e. Compositions comprising one or more phosphate binding agents for the prophylactic treatment of parturient hypocalcemia in ruminants (e.g., cattle), e.g., where the compositions are in one or more unit dosage forms, e.g., in one or more unit dosage forms. And wherein one or more unit dosage forms of the composition are manually administered per day to the gastrointestinal tract of the ruminant, or wherein the composition is provided in wet form. The present application also discloses compositions comprising one or more phosphate binding agents and one or more nutrients selected from the group consisting of minerals, vitamins and amino acids, and compositions comprising inhibitors of the small intestine Na-phosphate transporter for use in the prophylactic treatment of parturient hypocalcemia in ruminants, such as cattle. The phosphate binder is selected from aluminum salts, ferric salts, sevelamer salts and lanthanum salts formed with inorganic or organic acids, hydrates thereof or any mixture thereof.

The present invention is related to a novel pharmaceutical product containing iron and meglumine. In certain embodiments, the present invention is related to a novel injectable dosage form comprising ferric meglumine as a parenteral iron supplement to treat iron deficiency anemia. In certain embodiments, the present invention is related to a novel oral dosage form comprising ferric meglumine as iron supplement and / or phosphate binder.

The present invention relates to a phosphate binder and its use for the treatment of hyperphosphatemia. The phosphate binding agent at least comprises at least one guanidino-containing cross-linked polymer or a pharmaceutically acceptable salt thereof, the guanidino-containing cross-linked polymer is derived from polyallylamine or a pharmaceutically acceptable salt thereof, the guanidino-containing cross-linked polymer comprises a guanidino structural unit and a cross-linked structural unit, and the cross-linked structural unit is derived from polyallylamine or a pharmaceutically acceptable salt thereof. The guanidino structural unit and the cross-linked structural unit are respectively represented by formulae (1) and (2): # imgabs0 #

Provided herein are silica nanoparticles conjugated to a phosphate binding hexapeptide (PBH) via a linker amino acid residue and methods of making the same. Further provided are compositions including the nanoparticles and uses thereof in the treatment of hyperphosphatemia.

The present invention provides methods and pharmaceutical compositions for reducing serum phosphate levels in mammals and humans comprising the combined use of component (a) a phosphate binder; and component (b) a phosphate transport inhibitor, wherein a therapeutically effective amount of at least one of the component (a) and component (b) administered to the subject is lower than a therapeutically effective amount of the component administered in the absence of the other component.

To provide a pharmaceutical composition comprising certain phosphate binder particles having a certain particle size distribution.SOLUTION: A pharmaceutical composition comprises sucroferric oxyhydroxide particles having a particle size distribution, i) the pharmaceutical composition being selected from tablets, granules, or fine granules, ii) the sucroferric oxyhydroxide particles including more than 90 wt.% of sucroferric oxyhydroxide on a dry weight basis, iii) the particles of the sucroferric oxyhydroxide having a particle size distribution in which at least 80% (by volume) of the particles have a particle size in a range of 4 to 200 μm, iv) sucroferric oxyhydroxide phosphate binder particles accounting for more than 65 wt.% of the total weight of the pharmaceutical composition (dry weight basis), and v) the hardness of the tablet being in a range of 70 to 250 N.SELECTED DRAWING: Figure 1

The invention relates to the technical field of refractory bricks, in particular to a phosphate combined light-burned high-alumina brick for a high-erosion-resistance Mannheim furnace hearth, which is prepared from the following raw materials in parts by weight: 30 to 35 parts of homogenized alumina, 35 to 40 parts of calcined alumina, 8 to 10 parts of ball clay, 1.5 to 2 parts of mixed liquor, 4 to 6 parts of aluminum dihydrogen phosphate solution and 10 to 15 parts of filler. According to the invention, after zircon in the base material is activated by dilute nitric acid and modified by a silane coupling agent, the surface activity is improved, the zircon and a phosphate binding agent generate strong chemical bonding, nano zirconium oxide in the auxiliary material forms a stable crystal structure after hydrothermal synthesis and high-temperature calcination, and the base material and the auxiliary material are tightly combined in the mixing process; uniformly distributed reinforcing units are formed in the matrix, and through double mechanisms of physical filling and interface chemical bonding, the densification degree and integrity of the matrix are remarkably improved, so that the permeation path of a corrosive medium is effectively blocked, and the long service life of the material is ensured.

The present invention provides methods and pharmaceutical compositions for reducing serum phosphate levels in mammals and humans comprising the combined use of component (a) a phosphate binder; and component (b) a phosphate transport inhibitor.

The present invention provides a refractory mud for sliding water nozzle and a preparation method thereof, which belongs to the technical field of refractory materials, comprising the following steps: mixing aluminum hydroxide, water and phosphoric acid, heating reaction, after heating, adding boric acid, malic acid, tartaric acid and triethanolamine to continue the reaction, cooling to room temperature, filtering to obtain a modified phosphate binder; mixing zirconium powder and flake graphite, adding potassium chloride and sodium chloride to mix and stir, heating reaction in an inert gas, cooling, washing, and drying to obtain a nanocrystalline ZrC coated graphite material; ball milling and mixing fused magnesia, silicon powder and Al-Si alloy powder, adding modified magnesium aggregate, nanocrystalline ZrC coated graphite material and modified phosphate binder to mix, discharging and packaging to obtain refractory mud for sliding water nozzle. The present invention can improve the thermal shock resistance and slag erosion resistance of refractory mud for sliding water nozzle.

The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.